Thermo Fisher Scientific, the world leader in serving science, opens its inaugural office in Jakarta, Indonesia, marking a pivotal step in its strategic expansion into the country. To commemorate the milestone, the company hosted its first-ever Thermo Fisher Scientific Day for partners and industry leaders to discuss opportunities for scientific advancements in the fields of climate change, healthcare transformation, and sustainability solutions in Indonesia.

Thermo Fisher Scientific Day also marked the beginning of the company’s collaboration with two distinguished institutions in Indonesia, with the company signing two Memorandums of Understanding (MoUs) with the National Battery Research Institute (NBRI) and Mandaya Hospital Group.

Thermo Fisher's MoU with Mandaya Hospital Group is a commitment to advance stem cell research and production as well as facilitate CD19 CAR-T therapy development, a highly effective immunotherapy for patients with hematological malignancies. This partnership will leverage Thermo Fisher’s cutting-edge solutions, notably, the Gibco Cell Therapy Systems (CTS) portfolio of GMP-grade reagents and closed cell processing systems for mesenchymal stem cell (MSC) and CAR-T therapy production. Thermo Fisher will share their expertise by providing training and technical assistance to further Mandaya Hospital’s capabilities in translation research and clinical manufacturing.

These collaborations build on past partnerships forged by the company locally, including the National Research and Innovation Agency of Indonesia (Badan Riset dan Inovasi Nasional, BRIN) in 2023, which aims to strengthen research infrastructure and capabilities. The opening of Thermo Fisher’s official office will enable the company to provide closer support to its Indonesian partners and nurture local talent in its steadfast commitment to driving scientific progress in Indonesia.